Boston Scientific Corporation (BSX)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Boston Scientific Corporation (BSX) trades at $62.75 with AI Score 56/100 (Hold). Boston Scientific Corporation is a global medical device company focused on developing, manufacturing, and marketing interventional medical technologies. Market cap: 94B, Sector: Healthcare.
Last analyzed: Feb 9, 2026Boston Scientific Corporation (BSX) Healthcare & Pipeline Overview
Boston Scientific (BSX) is a leading medical device innovator, offering a diverse portfolio across interventional specialties, driving growth through strategic market expansion and technological advancements, reflected in its strong profit margin and established market presence, making it a compelling investment in the healthcare sector.
Investment Thesis
Boston Scientific presents a notable research candidate due to its diverse product portfolio, strong market position, and consistent financial performance. With a market capitalization of $113.11 billion and a profit margin of 14.4%, BSX demonstrates financial stability and growth potential. The company's commitment to innovation and strategic acquisitions positions it well for continued expansion in key markets. Growth catalysts include the increasing demand for minimally invasive procedures, advancements in medical technology, and the aging global population. The company's beta of 0.66 suggests lower volatility compared to the market, making it a noteworthy option for risk-averse investors. BSX's focus on expanding its product offerings and entering new markets should drive revenue growth and enhance shareholder value in the coming years.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $113.11B reflects strong investor confidence and market valuation.
- Profit margin of 14.4% indicates efficient operations and profitability.
- Gross margin of 69.0% demonstrates strong pricing power and cost management.
- P/E ratio of 39.13 suggests investors are willing to pay a premium for BSX's earnings, reflecting growth expectations.
- Beta of 0.66 indicates lower volatility compared to the market, making it a relatively stable investment.
Competitors & Peers
Strengths
- Diverse product portfolio across multiple medical specialties.
- Strong global presence and distribution network.
- Commitment to innovation and research and development.
- Established relationships with healthcare providers.
Weaknesses
- Exposure to regulatory risks and product recalls.
- Dependence on third-party suppliers and manufacturers.
- Competition from other large medical device companies.
- Potential for product liability claims.
Catalysts
- Upcoming: New product launches in key therapeutic areas, such as cardiology and neuromodulation.
- Ongoing: Expansion into emerging markets, driving revenue growth.
- Ongoing: Strategic acquisitions and partnerships, enhancing product portfolio and market access.
- Ongoing: Increasing demand for minimally invasive procedures.
- Ongoing: Advancements in medical technology, leading to new treatment options.
Risks
- Potential: Regulatory changes and increased scrutiny of medical devices.
- Potential: Product recalls and liability claims.
- Ongoing: Competition from other large medical device companies.
- Potential: Economic downturns and reduced healthcare spending.
- Ongoing: Dependence on third-party suppliers and manufacturers.
Growth Opportunities
- Expansion in Emerging Markets: Boston Scientific has the opportunity to expand its presence in emerging markets, such as China and India, where healthcare spending is increasing and access to advanced medical technologies is improving. These markets offer significant growth potential due to their large populations and unmet medical needs. The company can leverage its existing product portfolio and establish strategic partnerships to penetrate these markets and drive revenue growth. This expansion could contribute significantly to revenue growth within the next 3-5 years.
- Advancements in Neuromodulation: Boston Scientific can capitalize on the growing market for neuromodulation therapies, which are used to treat chronic pain, neurological disorders, and other conditions. The company's spinal cord stimulation and deep brain stimulation systems offer innovative solutions for patients who have not responded to traditional treatments. Continued investment in research and development in this area could lead to new product launches and increased market share. The global neuromodulation market is expected to reach billions of dollars in the coming years.
- Growth in Structural Heart Therapies: Boston Scientific can further expand its presence in the structural heart therapies market, which includes devices for repairing or replacing heart valves and treating other structural heart defects. The company's transcatheter aortic valve replacement (TAVR) and mitral valve repair technologies offer less invasive alternatives to traditional open-heart surgery. As the population ages and the prevalence of structural heart disease increases, the demand for these therapies is expected to grow. This market is projected to grow significantly over the next 5-10 years.
- Strategic Acquisitions and Partnerships: Boston Scientific can pursue strategic acquisitions and partnerships to expand its product portfolio, enter new markets, and gain access to innovative technologies. The company has a history of successful acquisitions, and it can continue to leverage this strategy to drive growth. Identifying and integrating complementary businesses can enhance Boston Scientific's competitive position and accelerate its growth trajectory. These partnerships can provide access to new technologies and markets within the next 2-3 years.
- Innovation in Remote Patient Monitoring: Boston Scientific can leverage its expertise in remote patient monitoring to develop new solutions for managing chronic conditions and improving patient outcomes. Remote monitoring devices and platforms can enable healthcare providers to track patients' vital signs, medication adherence, and other important parameters remotely, allowing for more timely interventions and personalized care. The market for remote patient monitoring is growing rapidly, driven by the increasing adoption of telehealth and the need to reduce healthcare costs. This is an ongoing opportunity with continuous advancement.
Opportunities
- Expansion in emerging markets.
- Development of new and innovative medical devices.
- Strategic acquisitions and partnerships.
- Growth in minimally invasive procedures.
Threats
- Changes in healthcare regulations and reimbursement policies.
- Economic downturns and reduced healthcare spending.
- Technological obsolescence and disruption.
- Increased competition from new entrants.
Competitive Advantages
- Strong brand reputation and established market presence.
- Extensive product portfolio across multiple medical specialties.
- Proprietary technologies and intellectual property.
- Global distribution network and strong relationships with healthcare providers.
- High barriers to entry due to regulatory requirements and technological complexity.
About BSX
Boston Scientific Corporation, founded in 1979 and headquartered in Marlborough, Massachusetts, has evolved into a global leader in the medical device industry. The company develops, manufactures, and markets a broad array of medical devices used in interventional medical specialties. Its operations are structured into three primary segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The MedSurg segment focuses on devices for diagnosing and treating gastrointestinal, pulmonary, urological, and pelvic conditions. The Rhythm and Neuro segment offers solutions for heart rhythm disorders, chronic pain management, and neurological conditions. The Cardiovascular segment provides interventional cardiology products, including drug-eluting stents, and structural heart therapies. Boston Scientific's comprehensive product portfolio includes stents, catheters, pacemakers, defibrillators, and neuromodulation systems. The company's products are used to treat a wide range of conditions, from heart disease and cancer to chronic pain and neurological disorders. Boston Scientific has a significant global presence, marketing its products in numerous countries and maintaining manufacturing facilities and research and development centers worldwide. The company competes with other major medical device manufacturers by focusing on innovation, strategic acquisitions, and expanding its product offerings to address unmet clinical needs.
What They Do
- Develops medical devices for interventional medical specialties.
- Manufactures medical devices used in various medical procedures.
- Markets medical devices globally to healthcare providers.
- Offers devices for diagnosing and treating gastrointestinal and pulmonary conditions.
- Provides devices for treating urological and pelvic conditions.
- Offers implantable cardioverter-defibrillators and pacemakers.
- Develops remote patient management systems.
- Provides technologies for treating heart rhythm disorders.
Business Model
- Develops and manufactures medical devices.
- Sells medical devices to hospitals, clinics, and other healthcare providers.
- Generates revenue through product sales and related services.
- Invests in research and development to innovate new products and improve existing ones.
Industry Context
Boston Scientific operates in the medical device industry, a sector characterized by continuous innovation and increasing demand driven by an aging global population and advancements in medical technology. The industry is highly competitive, with key players like Abbott (ABT), Danaher (DHR), and Medtronic vying for market share. The market is experiencing growth in minimally invasive procedures, advanced surgical technologies, and remote patient monitoring. Boston Scientific is well-positioned to capitalize on these trends with its diverse product portfolio and focus on innovation. The global medical device market is projected to reach hundreds of billions of dollars in the coming years, offering significant growth opportunities for companies like Boston Scientific.
Key Customers
- Hospitals and medical centers
- Cardiologists and electrophysiologists
- Gastroenterologists and pulmonologists
- Urologists and gynecologists
- Neurosurgeons and pain management specialists
Financials
Chart & Info
Boston Scientific Corporation (BSX) stock price: $62.75 (-0.18, -0.29%)
Latest News
-
Stocks making big moves yesterday: Avis Budget Group, Boston Scientific, CLEAR Secure, DNOW, and Comcast
Yahoo! Finance: BSX News · Mar 31, 2026
-
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Boston Scientific Corporation of Class Action Lawsuit and Upcoming Deadlines – BSX
globenewswire.com · Mar 31, 2026
-
Are Boston Scientific’s (BSX) New Trial Wins Quietly Redefining Its Minimally Invasive Care Advantage?
Yahoo! Finance: BSX News · Mar 31, 2026
-
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Boston Scientific Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – BSX
globenewswire.com · Mar 31, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BSX.
Price Targets
Consensus target: $107.79
MoonshotScore
What does this score mean?
The MoonshotScore rates BSX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
Stocks making big moves yesterday: Avis Budget Group, Boston Scientific, CLEAR Secure, DNOW, and Comcast
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Boston Scientific Corporation of Class Action Lawsuit and Upcoming Deadlines – BSX
Are Boston Scientific’s (BSX) New Trial Wins Quietly Redefining Its Minimally Invasive Care Advantage?
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Boston Scientific Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – BSX
Latest Boston Scientific Corporation Analysis
Eli Lilly's Taltz and Zepbound Combo Shows Promise, LLY Dips 2.09%
3 min readMarket Weakness Broadens as SPY Dips 1.71%, QQQ Down 1.95%
2 min readHealthcare Earnings Boost BSX, While EFX Revenue Grows 9% Amid Economic Headwinds
2 min readBitcoin and Ether Rebound Amid Derivatives Risk Reduction
3 min readTech Weakness Drags on Nasdaq, SPY Down 0.85%
3 min readBoston Scientific Corporation Stock: Key Questions Answered
What does Boston Scientific Corporation do?
Boston Scientific Corporation is a global medical device company that develops, manufactures, and markets a wide range of medical devices used in interventional medical specialties. The company operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Its products are used to diagnose and treat various medical conditions, including heart disease, cancer, chronic pain, and neurological disorders. Boston Scientific sells its products to hospitals, clinics, and other healthcare providers worldwide, generating revenue through product sales and related services. The company invests heavily in research and development to innovate new products and improve existing ones.
Is BSX stock worth researching?
BSX stock presents a mixed outlook. The company's strong market position, diverse product portfolio, and commitment to innovation make it an attractive investment. However, the stock's high P/E ratio of 39.13 suggests that it may be overvalued. Investors may want to evaluate the company's growth potential, financial performance, and competitive landscape before making a decision. The increasing demand for minimally invasive procedures and the company's expansion into emerging markets could drive future growth. A balanced analysis of these factors is crucial before considering BSX worth researching.
What are the main risks for BSX?
Boston Scientific faces several risks, including regulatory changes, product recalls, competition, and economic downturns. Changes in healthcare regulations and reimbursement policies could negatively impact the company's revenue and profitability. Product recalls and liability claims could result in significant financial losses and reputational damage. Competition from other large medical device companies could erode market share. Economic downturns and reduced healthcare spending could reduce demand for the company's products. These risks should be carefully considered by investors.
What are the key factors to evaluate for BSX?
Boston Scientific Corporation (BSX) currently holds an AI score of 56/100, indicating moderate score. The stock trades at a P/E of 32.2x, near the S&P 500 average (~20-25x). Analysts target $107.79 (+72% from $62.75). Key strength: Diverse product portfolio across multiple medical specialties.. Primary risk to monitor: Potential: Regulatory changes and increased scrutiny of medical devices.. This is not financial advice.
How frequently does BSX data refresh on this page?
BSX prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven BSX's recent stock price performance?
Recent price movement in Boston Scientific Corporation (BSX) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. The current analyst target of $107.79 implies 72% upside from here. Notable catalyst: Diverse product portfolio across multiple medical specialties.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider BSX overvalued or undervalued right now?
Determining whether Boston Scientific Corporation (BSX) is overvalued or undervalued requires examining multiple metrics. Its P/E ratio is 32.2. Analysts target $107.79 (+72% from current price), suggesting analysts see upside potential. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying BSX?
Before investing in Boston Scientific Corporation (BSX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Stock data pending update.